N-acetyl-cysteine (NAC) & Glutathione: The Master Antioxidant Connection

Table of Contents

1. What Is Glutathione?
2. Biochemistry: Three Amino Acids, Two Steps
3. Why Cysteine Is Rate-Limiting
4. Why NAC Works — The Acetyl Protection Trick
5. What Glutathione Does
6. Conditions of Glutathione Depletion
7. Evidence That Oral NAC Raises Glutathione
8. GlyNAC: The Glycine + NAC Protocol
9. Oral vs IV Bioavailability
10. Alternatives and Cofactors
11. Dosing for Glutathione Support
12. Safety
13. Key Research Papers
14. Connections
15. Featured Videos

What Is Glutathione?

Glutathione is a tripeptide — a small protein made of three amino acids: glutamate, cysteine, and glycine. Its full chemical name is gamma-L-glutamyl-L-cysteinyl-glycine. The name matters because glutathione's peptide bond between glutamate and cysteine is unusual — it uses glutamate's gamma-carboxyl group rather than the standard alpha-carboxyl. This gamma-bond makes glutathione resistant to most cellular peptidases, which is how the body keeps its intracellular glutathione pool stable and metabolically durable at concentrations of 1–10 millimolar — among the highest small-molecule concentrations of any cellular metabolite.

All the antioxidant chemistry happens at one specific atom: the sulfur of cysteine's thiol group (–SH). When glutathione donates an electron to neutralize a reactive oxygen species, two glutathione molecules pair up and form an oxidized dimer called GSSG (glutathione disulfide). Healthy cells maintain a GSH:GSSG ratio above 100:1. When that ratio drops below ~10:1, the cell is in severe oxidative stress.

Biochemistry: Three Amino Acids, Two Steps

Glutathione is synthesized in the cytosol of essentially every cell — the liver is the dominant systemic producer. Synthesis happens in two ATP-dependent steps:

1. Step 1 (rate-limiting): Glutamate-cysteine ligase (GCL). Glutamate + cysteine + ATP → gamma-glutamylcysteine + ADP + Pi. GCL is feedback-inhibited by glutathione itself (Ki ~2.3 mM), which keeps production in check. Under oxidative stress the Nrf2/Keap1 transcription factor system induces GCL expression through antioxidant response elements (AREs) in its promoter, ramping up synthetic capacity.
2. Step 2: Glutathione synthetase (GS). Gamma-glutamylcysteine + glycine + ATP → glutathione + ADP + Pi. Not rate-limiting under normal conditions, but glycine can become co-limiting in aging and protein restriction.

The gamma-glutamyl cycle (discovered by Alton Meister) describes how glutathione is continuously degraded and resynthesized. Gamma-glutamyl transpeptidase (GGT) on the outer cell membrane cleaves extracellular glutathione; the liberated cysteinylglycine is hydrolyzed to cysteine and glycine; those amino acids are re-imported for resynthesis. This is how the liver exports glutathione into bile and plasma, and how peripheral tissues (the kidney especially) recover glutathione's building blocks.

Why Cysteine Is Rate-Limiting

Of the three amino acid substrates, glutamate is abundant and not limiting, glycine is sometimes co-limiting, and cysteine is almost always rate-limiting. Three reasons:

1. Free cysteine is toxic at high levels. Cysteine can act as an excitotoxin on NMDA receptors and autoxidize to cystine in the plasma, generating hydrogen peroxide. The body therefore keeps intracellular free cysteine extremely low — roughly 10–100 micromolar in hepatocytes. Cells must actively import cysteine or its oxidized dimer cystine through dedicated transporters (ASC for cysteine, xCT / system xc- for cystine).
2. The thiol is vulnerable to oxidation. Free cysteine in aqueous solution at neutral pH autoxidizes to cystine in minutes to hours. Delivering reduced cysteine to cells is mechanically harder than delivering any other amino acid.
3. Dietary cysteine is limited. Methionine can be converted to cysteine via the trans-sulfuration pathway, but the enzymatic flux is modest and requires pyridoxal phosphate (vitamin B6) as a cofactor.

The practical implication: whether glutathione goes up or down in a given tissue is almost always about whether cysteine supply is keeping up with demand.

Why NAC Works — The Acetyl Protection Trick

N-acetylcysteine is just cysteine with an acetyl group (–COCH3) attached to the alpha-amino nitrogen. That single modification changes everything about its pharmacology:

1. Thiol protection. The acetyl group sterically and electronically stabilizes the thiol, so NAC survives as a stable pill, capsule, or effervescent tablet at room temperature. Pure cysteine in solution oxidizes too quickly for reliable manufacturing.
2. Reduced toxicity. NAC does not carry cysteine's excitotoxic liability because the acetylated amine can't interact with NMDA receptors the same way.
3. Better oral tolerability. Free cysteine at supplemental doses causes GI distress and has a stronger sulfur odor. NAC is by no means odorless (it still smells like rotten eggs) but it is tolerated well enough for multi-gram daily dosing.
4. Deacetylation in vivo. Once absorbed, NAC is rapidly deacetylated by cellular acylase I — most heavily in liver, kidney, and small intestine — to release free cysteine exactly where it is needed. The acetyl group has done its job of getting cysteine through manufacturing, storage, packaging, swallowing, digestion, and absorption.

Beyond its prodrug role, NAC has two direct activities of its own: it is a mucolytic (cleaving disulfide bonds in mucus glycoproteins — the basis of its original 1963 respiratory use) and a direct antioxidant (its free thiol scavenges hydroxyl radicals and hypochlorous acid without needing to be converted to glutathione first).

What Glutathione Does

Master Antioxidant

Glutathione is the substrate for glutathione peroxidase (GPx), a selenium-dependent enzyme family that reduces hydrogen peroxide to water and lipid hydroperoxides to lipid alcohols. This is the body's primary defense against peroxide-mediated oxidative injury. Oxidized glutathione (GSSG) is recycled back to GSH by glutathione reductase, which uses NADPH from the pentose phosphate pathway.

Phase II Detoxification (Liver)

Glutathione S-transferases (GSTs) conjugate glutathione to electrophilic xenobiotics — including the reactive acetaminophen metabolite NAPQI, aflatoxin epoxides, many chemotherapy drugs, and environmental pollutants. The resulting glutathione-conjugate is exported, converted to a mercapturic acid, and excreted in urine. This is why NAC is the FDA-approved acetaminophen antidote: it replenishes the glutathione needed to neutralize NAPQI before it can bind hepatocyte proteins.

Immune Cell Function

T lymphocytes, natural killer cells, and macrophages require high intracellular glutathione for proliferation, cytokine production, and cytotoxic function. Low glutathione biases the Th1/Th2 balance toward Th2 dominance, impairs IL-2 signaling, and reduces antigen-presenting capability.

Mitochondrial Protection

Mitochondria have a separate glutathione pool imported across the inner membrane via dicarboxylate and 2-oxoglutarate carriers. This pool detoxifies the superoxide continuously generated at Complex I and Complex III of the electron transport chain. Mitochondrial glutathione depletion is a central event in acetaminophen hepatotoxicity, ischemia-reperfusion injury, and neurodegenerative disease.

Regenerating Other Antioxidants

Glutathione recycles oxidized vitamin C (dehydroascorbate) back to reduced ascorbate, and indirectly regenerates vitamin E. This puts GSH at the top of the cellular antioxidant hierarchy.

Conditions of Glutathione Depletion

• Aging. Erythrocyte and tissue glutathione fall roughly 30–50% between ages 20 and 80. Reduced GCL expression and reduced cysteine + glycine flux are the mechanisms.
• HIV infection. Plasma and lymphocyte glutathione are markedly low; Herzenberg and colleagues showed that low glutathione predicts HIV mortality independent of CD4 count.
• Chronic alcoholism. Ethanol depletes hepatic mitochondrial glutathione by 40–60% through CYP2E1-generated ROS and reduced cysteine availability from malnutrition.
• Acetaminophen overdose. CYP2E1 oxidizes 5–10% of a dose to NAPQI, which depletes glutathione rapidly; centrilobular necrosis follows.
• COPD, cystic fibrosis, chronic lung inflammation. Cigarette smoke and chronic neutrophilic inflammation consume airway glutathione.
• Type 2 diabetes, metabolic syndrome, cardiovascular disease. Hyperglycemia-driven mitochondrial superoxide depletes glutathione systemically.
• Chronic kidney disease and hemodialysis. Dialysis membranes, chronic iron therapy, and uremia all consume glutathione.
• Parkinson's disease and Alzheimer's disease. Substantia nigra and hippocampal glutathione are reduced early in both diseases.
• Critical illness, sepsis, major surgery, burns, chemotherapy. Acute consumption outpaces synthesis.
• Genetic. GCLC promoter polymorphisms, glutathione synthetase deficiency (rare).
• Nutritional. Chronic protein malnutrition, low-selenium diets (impaired GPx), low-B6 (blocked transsulfuration).

Evidence That Oral NAC Raises Glutathione

This is the key empirical question — does oral NAC actually raise glutathione in humans, or just raise plasma NAC?

Healthy Adults

• Kleinveld 1992 (Eur J Clin Pharmacol): 600 mg oral NAC raised plasma free cysteine within 1–2 hours and modestly raised plasma glutathione.
• Bridgeman 1991 (Thorax): 600 mg NAC three times daily for 5 days in healthy subjects significantly raised bronchoalveolar lavage glutathione — proving oral NAC reaches the lung in active form.

Aging — The Sekhar Studies

Rajagopal Sekhar's group at Baylor College of Medicine has studied age-related glutathione deficiency. In the American Journal of Clinical Nutrition in 2011, 8 older adults had lower red-cell glutathione than 8 younger adults (1.12 versus 2.08 mmol/L), along with lower red-cell glycine and cysteine and a slower glutathione synthesis rate. After 2 weeks of cysteine and glycine supplementation, the older group's glutathione concentration was 94.6% higher and plasma oxidative stress and F2-isoprostanes (a marker of lipid peroxidation) were significantly lower; the authors reported no remaining differences from the younger group. The study had no placebo group.

The group's 2021 pilot in Clinical and Translational Medicine was a 36-week open-label study with no placebo group: 8 older adults received glycine 1.33 mmol/kg/day and cysteine 0.81 mmol/kg/day (given as NAC) for 24 weeks, followed by 12 weeks without, and 8 young adults were studied once at baseline for comparison. The authors reported that GlyNAC corrected glutathione deficiency and oxidative stress and improved mitochondrial function, cognition, gait speed and muscle strength, among other measures, and that the benefits declined after stopping. A separate randomized, placebo-controlled trial by the same group (published 2023) gave GlyNAC or placebo to 24 older adults for 16 weeks and reported improvements with GlyNAC but not placebo.

HIV — The Herzenberg Studies

Leonard and Leonore Herzenberg at Stanford showed in PNAS 1997 that HIV patients had severely depleted T-cell glutathione and that NAC 3,200–8,000 mg/day for 8 weeks restored T-cell glutathione toward normal. A retrospective survival analysis found 2-year mortality of 40% in low-glutathione patients versus 8% in replenished patients — a striking result that helped establish NAC as a credible HIV adjunct.

COPD

The PANTHEON trial (Zheng 2014, Lancet Respir Med) showed NAC 600 mg twice daily reduced COPD exacerbations by 22% over 1 year — most likely through raised airway glutathione and reduced oxidative stress. This is a large, rigorous outcome-level confirmation of biological activity.

Psychiatric

Berk's schizophrenia trial (2008, Biol Psychiatry) used NAC 2 g/day for 24 weeks and showed PANSS-measurable symptom improvement, with mechanistic underpinning in reduced cortical glutathione (measured by magnetic resonance spectroscopy in schizophrenia) being restored.

Summary

Across oral doses of 600–2,400 mg/day, most studies report a 30–90% rise in whole-blood or erythrocyte glutathione within 2–8 weeks. Plasma free cysteine roughly doubles within 1–2 hours after each dose. The "low bioavailability" of intact NAC (4–10%) is misleading because the liver and gut aggressively deacetylate NAC to cysteine, which is used directly for glutathione synthesis where it is needed — not as a free NAC molecule circulating in plasma.

GlyNAC: The Glycine + NAC Protocol

Sekhar's group proposes that glycine, not only cysteine, runs short in aging, and that supplying both is needed to restore glutathione synthesis; it named the combination GlyNAC. Nearly all of the human GlyNAC evidence comes from this one group. In the 2021 open-label pilot (8 older adults, 24 weeks of glycine 1.33 mmol/kg/day and cysteine 0.81 mmol/kg/day as NAC, no placebo group), the authors reported improvements in:

• Erythrocyte glutathione (restored to young-adult levels)
• Mitochondrial fuel oxidation (measured with calorimetry and stable-isotope tracers)
• Plasma markers of endothelial function
• Insulin resistance (HOMA-IR)
• Grip strength, gait speed and 6-minute walk distance
• Cognitive test scores
• Inflammatory markers (IL-6, TNF-alpha)

The group's randomized, placebo-controlled trial (Kumar 2023) gave GlyNAC (12) or an alanine placebo (12) to 24 older adults for 16 weeks and reported that GlyNAC, and not placebo, improved glutathione, oxidative stress, mitochondrial function, inflammation, insulin resistance, physical function and waist circumference; its PubMed abstract does not state the dose. In mice, a 2022 study from the same group reported that GlyNAC-fed animals lived 24% longer; this has not been tested in people.

An independent placebo-controlled trial (Lizzo 2022) gave 114 healthy older adults glycine and NAC at fixed doses of 2.4, 4.8 or 7.2 g/day combined (1:1), or placebo, for 2 weeks. GlyNAC was well tolerated but did not raise total glutathione or the reduced-to-oxidized glutathione ratio, its primary endpoint. Most of its authors were employees of a nutrition company whose subsidiary, per the paper's disclosure, holds patents on and markets glycine-and-NAC products. No trial found in PubMed compares the Baylor weight-based dose with lower doses over months, so the dose needed for any effect is not known.

Oral vs IV Bioavailability

Oral NAC. Intact-molecule bioavailability is 4–10% due to extensive first-pass metabolism (Borgstrom 1986, Eur J Clin Pharmacol). Tmax is 1–2 hours. Plasma half-life of total NAC is 2–6 hours, shorter for the reduced form. But because gut and liver deacetylate NAC directly into the cysteine and glutathione pools, the "low bioavailability" figure understates therapeutic effect.

IV NAC. 100% bioavailability, reserved for hospital settings like acetaminophen overdose (300 mg/kg total over 21 hours in the Prescott regimen). Plasma concentrations are 10-fold higher than with oral dosing.

CNS penetration. Cysteine crosses the blood-brain barrier slowly via the ASC transporter. Brain glutathione does rise measurably on magnetic resonance spectroscopy after oral NAC in Parkinson's and Gaucher disease patients (Holmay 2013, Clin Neuropharmacol). This supports NAC's psychiatric-neurological applications.

Alternatives and Cofactors

• Liposomal glutathione. Sinha 2018 (Eur J Clin Nutr): 500 mg/day liposomal glutathione raised blood glutathione ~40% at 1 month and doubled NK-cell activity. More efficient per milligram than oral non-liposomal glutathione.
• Direct oral glutathione (non-liposomal). Results differ by trial. Allen 2011 (J Altern Complement Med): 500 mg twice daily for 4 weeks in 40 healthy adults produced no significant change in oxidative-stress markers or red-cell glutathione. Richie 2015 (Eur J Nutr): 250 or 1,000 mg/day for 6 months raised glutathione in blood; at 6 months the high dose had raised mean levels 30–35% in red cells, plasma and lymphocytes.
• Whey protein. Rich in cysteine and glutamylcysteine, especially in undenatured preparations. Micke 2001 (Eur J Nutr): 40 g/day whey protein isolate raised lymphocyte glutathione in HIV and hepatitis patients.
• Glycine. Needed for Step 2 of glutathione synthesis; the Baylor group proposes it is co-limiting with cysteine in aging. The doses used in the GlyNAC trials are given in the GlyNAC section above.
• Selenium. Required cofactor for glutathione peroxidase. RDA 55 micrograms, upper limit 400 micrograms. Brazil nuts, seafood, and organ meats are dietary sources.
• Alpha-lipoic acid. 300–600 mg/day. Regenerates glutathione indirectly and recycles other antioxidants.
• Sulforaphane (broccoli sprouts). A potent Nrf2 activator; induces the GCL gene rather than supplying substrate — a complementary mechanism to NAC.
• Silymarin (milk thistle). Raises hepatic glutathione by roughly 35% in animal and some human studies.
• Curcumin, resveratrol, EGCG (green tea). Mild Nrf2 activators.
• Dietary cysteine/methionine. Eggs, poultry, fish, legumes, garlic, onions, cruciferous vegetables.

Dosing for Glutathione Support

• General antioxidant / preventive: 600–1,200 mg/day in divided doses. Most effective as 600 mg BID.
• Active immune/respiratory support (COPD dose): 600 mg twice daily (PANTHEON-validated).
• Psychiatric adjunct: 2,000–2,400 mg/day divided, 8–12 weeks minimum for effect.
• GlyNAC (as studied): the Baylor 2021 pilot used glycine 1.33 mmol/kg/day and cysteine 0.81 mmol/kg/day (given as NAC) for 24 weeks; the independent Lizzo 2022 trial used 2.4, 4.8 or 7.2 g/day of glycine and NAC combined for 2 weeks and did not meet its primary endpoint.
• Timing: With or without food. Empty stomach absorbs slightly faster; with food reduces nausea.
• Form: Effervescent tablets and oral solutions are better tolerated than capsules because the sulfurous odor drives nausea.

Safety

• Most common: nausea, dyspepsia, diarrhea, sulfurous odor/taste. Usually mild and dose-related.
• Inhaled NAC: can trigger bronchospasm in asthmatics; pre-treat with a bronchodilator.
• IV NAC: anaphylactoid (histamine-mediated) reactions in 10–20% during first loading infusion.
• Drug interaction — nitroglycerin: in a trial of 46 patients with severe unstable angina, intravenous NAC added to intravenous nitroglycerin was followed by symptomatic low blood pressure in 7 of 24 patients, versus none of 22 on nitroglycerin alone (Horowitz 1988); in a randomized trial of 200 patients, transdermal nitroglycerin plus oral NAC was associated with side effects, mainly intolerable headache, in 35% (Ardissino 1997).
• Theoretical: chelates copper and zinc in very large doses.
• No tolerance, dependence, or withdrawal. NAC does not require dose escalation over time.

The FDA has taken an ambiguous position on NAC's status as a dietary supplement since 2020 because of its approved drug history, but has exercised enforcement discretion. It has been sold over-the-counter in Europe for decades as a mucolytic.

Key Research Papers

1. Sekhar RV, Patel SG, Guthikonda AP, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr 2011;94(3):847–853. PubMed PMID: 21795440.
2. Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition. Clin Transl Med 2021;11(3):e372. PubMed PMID: 33783984.
3. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. PNAS 1997;94(5):1967–1972. PubMed PMID: 9050888.
4. De Rosa SC, Zaretsky MD, Dubs JG, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000;30(10):915–929. PubMed PMID: 11029607.
5. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with NAC. Thorax 1991;46(1):39–42. PubMed PMID: 1871695.
6. Kleinveld HA, Demacker PN, Stalenhoef AF. Failure of NAC to reduce LDL oxidizability in healthy subjects. Eur J Clin Pharmacol 1992;43(6):639–642. Search PubMed.
7. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of NAC in man. Eur J Clin Pharmacol 1986;31(2):217–222. PMID 3803419.
8. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized NAC. Eur J Clin Pharmacol 1988;34(1):77–82. PubMed PMID: 3360052.
9. Lu SC. Glutathione synthesis. Biochim Biophys Acta 2013;1830(5):3143–3153. PubMed PMID: 22995213.
10. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009;30(1–2):42–59. PubMed PMID: 18601945.
11. Droge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000;59(4):595–600. PubMed PMID: 11115795.
12. Mari M, Morales A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009;11(11):2685–2700. PubMed PMID: 19558212.
13. Holmay MJ, Terpstra M, Coles LD, et al. NAC boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 2013;36(4):103–106. PubMed PMID: 23860343.
14. Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr 2018;72(1):105–111. PubMed PMID: 28853742.
15. Richie JP Jr, Nichenametla S, Neidig W, et al. RCT of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015;54(2):251–263. PubMed PMID: 24791752.
16. Micke P, Beeh KM, Buhl R. Effects of long-term supplementation with whey proteins on plasma glutathione levels of HIV-infected patients. Eur J Nutr 2002;41(1):12–18. PubMed PMID: 11990003.
17. Atkuri KR, Mantovani JJ, Herzenberg LA. NAC — a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7(4):355–359. PubMed PMID: 17602868.
18. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol overdose with NAC. Lancet 1977;2(8035):432–434. PMID 71287.
19. Zheng JP, Wen FQ, Bai CX, et al. Twice daily NAC 600 mg for exacerbations of COPD (PANTHEON). Lancet Respir Med 2014;2(3):187–194. PubMed PMID: 24621680.
20. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral NAC, a glutathione prodrug, modulates inflammation in cystic fibrosis. PNAS 2006;103(12):4628–4633. PubMed PMID: 16537378.
21. Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. J Gerontol A Biol Sci Med Sci 2023;78(1):75–89. PubMed PMID: 35975308.
22. Lizzo G, Migliavacca E, Lamers D, et al. A randomized controlled clinical trial in healthy older adults to determine efficacy of glycine and N-acetylcysteine supplementation on glutathione redox status and oxidative damage. Front Aging 2022;3:852569. PubMed PMID: 35821844.
23. Kumar P, Osahon OW, Sekhar RV. GlyNAC (glycine and N-acetylcysteine) supplementation in mice increases length of life by correcting glutathione deficiency, oxidative stress, mitochondrial dysfunction, abnormalities in mitophagy and nutrient sensing, and genomic damage. Nutrients 2022;14(5):1114. PubMed PMID: 35268089.
24. Horowitz JD, Henry CA, Syrjanen ML, et al. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation 1988;77(4):787–794. PubMed PMID: 3127076.
25. Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol 1997;29(5):941–947. PubMed PMID: 9120179.
26. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med 2011;17(9):827–833. PubMed PMID: 21875351.

PubMed Topic Searches

Selected PubMed topic searches relevant to glutathione biology, NAC-driven glutathione repletion, and downstream antioxidant effects.

1. PubMed: NAC and glutathione synthesis
2. PubMed: Glutathione peroxidase and oxidative stress
3. PubMed: Glutathione S-transferase and detoxification
4. PubMed: Glutathione and hepatocyte function
5. PubMed: Glutathione decline with aging
6. PubMed: Oral glutathione bioavailability
7. PubMed: Liposomal glutathione absorption
8. PubMed: Glycine and glutathione synthesis
9. PubMed: Glutamate-cysteine ligase (GCLC)
10. PubMed: Nrf2 and glutathione antioxidant response
11. PubMed: Glutathione and neurodegeneration
12. PubMed: Glutathione and mitochondrial function

Back to Table of Contents

Connections

• Free Radicals & Your Antioxidant Network — interactive animation
• NAC
• Cysteine
• Glycine
• Selenium
• Vitamin C
• Vitamin E
• NAC and Liver Health
• NAC and Kidney Health
• NAC and Respiratory Health
• Glutamine
• Oxidative Stress
• Liver Cleansing
• Longevity Protocols
• Milk Thistle
• Methionine
• COPD
• Schizophrenia
• Turmeric
• Conditions on this site that reference this page: Cataracts · Acute Respiratory Distress Syndrome (ARDS)

↑ Back to Table of Contents

×

Featured Videos